Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peggy Geluykens

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|July 4, 2013
A fluorescence-based high-throughput screening assay to identify HIV-1 inhibitorsPeggy Geluykens, Koen Van Acker, Johan Vingerhoets, et al.
Virology|April 28, 2010
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profilesOlivia Goethals, Ann Vos, Marcia Van Ginderen, et al.
Plos Computational Biology|December 6, 2023
Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamicsClare P McCormack, Olivia Goethals, Nele Goeyvaerts, et al.
Assay and Drug Development Technologies|October 23, 2013
An automated time-of-drug-addition assay to routinely determine the mode of action of HIV-1 inhibitorsMarnix Van Loock, Christel Van den Eynde, John Hansen, et al.
Plos One|December 2, 2011
Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical developmentGerard J P van Westen, Jörg K Wegner, Peggy Geluykens, et al.
ACS Medicinal Chemistry Letters|December 15, 2022
From Oxetane to Thietane: Extending the Antiviral Spectrum of 2'-Spirocyclic Uridines by Substituting Oxygen with SulfurSandrine Grosse, Abdellah Tahri, Pierre Raboisson, et al.
Journal of Virology|August 22, 2008
Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitorsOlivia Goethals, Reginald Clayton, Marcia Van Ginderen, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 8, 2009
Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion proteinDirk Roymans, Hendrik L De Bondt, Eric Arnoult, et al.
Nature Communications|July 19, 2024
Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B/NS3 and blocks replication organelle formationDominik Kiemel, Ann-Sophie Helene Kroell, Solène Denolly, et al.
Antiviral Research|October 18, 2017
Characterization of a dengue NS4B inhibitor originating from an HCV small molecule libraryIlane Hernandez-Morales, Peggy Geluykens, Marleen Clynhens, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|July 4, 2013
A fluorescence-based high-throughput screening assay to identify HIV-1 inhibitorsPeggy Geluykens, Koen Van Acker, Johan Vingerhoets, et al.
Virology|April 28, 2010
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profilesOlivia Goethals, Ann Vos, Marcia Van Ginderen, et al.
Plos Computational Biology|December 6, 2023
Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamicsClare P McCormack, Olivia Goethals, Nele Goeyvaerts, et al.
Assay and Drug Development Technologies|October 23, 2013
An automated time-of-drug-addition assay to routinely determine the mode of action of HIV-1 inhibitorsMarnix Van Loock, Christel Van den Eynde, John Hansen, et al.
Plos One|December 2, 2011
Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical developmentGerard J P van Westen, Jörg K Wegner, Peggy Geluykens, et al.
ACS Medicinal Chemistry Letters|December 15, 2022
From Oxetane to Thietane: Extending the Antiviral Spectrum of 2'-Spirocyclic Uridines by Substituting Oxygen with SulfurSandrine Grosse, Abdellah Tahri, Pierre Raboisson, et al.
Journal of Virology|August 22, 2008
Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitorsOlivia Goethals, Reginald Clayton, Marcia Van Ginderen, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 8, 2009
Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion proteinDirk Roymans, Hendrik L De Bondt, Eric Arnoult, et al.
Nature Communications|July 19, 2024
Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B/NS3 and blocks replication organelle formationDominik Kiemel, Ann-Sophie Helene Kroell, Solène Denolly, et al.
Antiviral Research|October 18, 2017
Characterization of a dengue NS4B inhibitor originating from an HCV small molecule libraryIlane Hernandez-Morales, Peggy Geluykens, Marleen Clynhens, et al.
Pageof 2